These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
804 related articles for article (PubMed ID: 15623594)
1. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594 [TBL] [Abstract][Full Text] [Related]
2. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609 [TBL] [Abstract][Full Text] [Related]
3. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420 [TBL] [Abstract][Full Text] [Related]
4. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673 [TBL] [Abstract][Full Text] [Related]
5. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
6. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183 [TBL] [Abstract][Full Text] [Related]
7. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
8. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982 [TBL] [Abstract][Full Text] [Related]
9. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743 [TBL] [Abstract][Full Text] [Related]
10. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769 [TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011 [TBL] [Abstract][Full Text] [Related]
13. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940 [TBL] [Abstract][Full Text] [Related]
15. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855 [TBL] [Abstract][Full Text] [Related]
16. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573 [TBL] [Abstract][Full Text] [Related]
17. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Al-Kuraya K; Siraj AK; Bavi P; Al-Jommah N; Ezzat A; Sheikh S; Amr S; Al-Dayel F; Simon R; Guido S Hum Pathol; 2006 Apr; 37(4):453-7. PubMed ID: 16564920 [TBL] [Abstract][Full Text] [Related]
18. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541 [TBL] [Abstract][Full Text] [Related]
19. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. Hata A; Yoshioka H; Fujita S; Kunimasa K; Kaji R; Imai Y; Tomii K; Iwasaku M; Nishiyama A; Ishida T; Katakami N J Thorac Oncol; 2010 Oct; 5(10):1524-8. PubMed ID: 20808254 [TBL] [Abstract][Full Text] [Related]
20. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Hsieh MH; Fang YF; Chang WC; Kuo HP; Lin SY; Liu HP; Liu CL; Chen HC; Ku YC; Chen YT; Chang YH; Chen YT; Hsi BL; Tsai SF; Huang SF Lung Cancer; 2006 Sep; 53(3):311-22. PubMed ID: 16870303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]